Willson ML et al., 2019-09-02: Cochrane review of 29 trials and 41,911 randomised women comparing taxane-containing with non-taxane adjuvant regimens for operable early breast cancer. Overall survival HR 0.87 (95% CI 0.83-0.92; high-certainty), with benefit persisting in head-to-head comparisons.
This review of studies supports the use of taxane-containing adjuvant chemotherapy regimens, with improvement in overall survival and disease-free survival for women with operable early breast cancer.
Abstract (AUTHORS' CONCLUSIONS)
Willson ML et al., 2019-09-02: Cochrane review of 29 trials and 41,911 randomised women comparing taxane-containing with non-taxane adjuvant regimens for operable early breast cancer. Overall survival HR 0.87 (95% CI 0.83-0.92; high-certainty), with benefit persisting in head-to-head comparisons. Funder: internal – NHMRC Clinical Trials Centre, University of Western Australia, Sir Charles Gairdner and Royal Perth Hospitals; external – National Breast Cancer Centre, Australia (public/charitable, not industry). Conflicts: all authors 'none known'. Drugs: paclitaxel and docetaxel (makers not named; no industry funding permitted under Cochrane policy CHJ-24). Comparator: same regimen without a taxane or with another drug substituted. Authors state an update is 'highly unlikely'. PMC6718224. Study type: review.
